

Lecanemab: Understanding the New Drug

BrainTalk Live: 31 January 2023


Erik Johnson, MD, PhD Department of Neurology Goizueta Alzheimer's Disease Research Center Center for Neurodegenerative Disease Emory University School of Medicine



Goizueta Alzheimer's Disease Research Center

www.alzheimers.emory.edu

The Evolution of Alzheimer's Disease



 $\langle \rangle$


EMORY



The Effect of Lecanemab

Amyloid Burden







Potential Risks of Lecanemab

- Infusion-related reaction (~26%)
- Excessive brain inflammation (~3%)
- Significant brain bleeding (~0.6%)

Who Is Eligible?

Must Be/Have:

• Age 50-90

EMORY

- Amyloid in brain
- Mild symptoms
- Recent clinical assessment (w/in 3 mo)
- Recent MRI scan (w/in 1 yr), ability to receive more scans
- Informant/care partner/family available to attend follow-up visits

Cannot Be/Have:

- Evidence of significant strokes or bleeding in the brain
- Seizure within the past 12 months
- Unstable severe psychiatricillness in past 6 months
- A bleeding disorder
- Severe uncontrolled diabetes or hypertension
- Significant heart problems (excluding atrial fibrillation)
- Severe kidney problems
- Alcohol and substance abuse problems in the past year
- Undergoing active cancer treatment
- Recent severe illness (e.g., pneumonia)
- Be immunosuppressed



Special Considerations

- Blood thinners (anticoagulation)
- APOE4 genotype
 - Different risk/benefit calculation?
- Cost and Access
 - Insurance coverage not yet available
- Infusion every 2 weeks
- Duration of Treatment?
 - Maintenance treatment?
- Subjects currently enrolled in clinical trials?